ICER Reveals Final Evidence Report on Three Multiple Myeloma Therapies

The Institute for Clinical and Economic Review (ICER) has announced a Final Evidence Report evaluating three therapies for use in multiple myeloma. ICER determined efficacy and cost-effectiveness of idecabtagene vicleucel, ciltacabtagene autoleucel, and belantamab mafodotin-blmf. Additional therapies are needed as many patients become resistant to treatments. An independent appraisal committee compared these therapies to usual care.

ICER President Steven Pearson remarks, “[T]hese three new therapies with new mechanisms of action represent a very important expansion of the clinical options available to patients and oncologists,” adding, “Data are extremely limited at this time for the two CAR-Ts, and important evidence gaps remain to be filled, but having a new innovative approach become available for patients with multiple myeloma is something to celebrate.” Read more here.

(Source: ICER, 5/11/21)